Fagan Associates
VRTX icon

Fagan Associates’s Vertex Pharmaceuticals VRTX Stock Holding History

Fagan Associates’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$14.4M Buy
27,475
+1,046
+4% +$536K 1.67% 14
2026
Q2 		$13.1M Sell
26,429
-124
-0.5% -$55K 1.62% 16
2026
Q1 		$11.9M Sell
26,553
-13
-0% -$6.06K 1.65% 17
2025
Q4 		$12M Buy
26,566
+260
+1% +$112K 1.61% 18
2025
Q3 		$10.3M Buy
26,306
+111
+0.4% +$46.4K 1.42% 21
2025
Q2 		$11.7M Sell
26,195
-90
-0.3% -$41.5K 1.8% 15
2025
Q1 		$12.7M Sell
26,285
-233
-0.9% -$109K 2.13% 13
2024
Q4 		$10.7M Buy
26,518
+93
+0.4% +$43.1K 1.7% 14
2024
Q3 		$12.3M Sell
26,425
-70
-0.3% -$33.6K 2.06% 10
2024
Q2 		$12.4M Buy
26,495
+557
+2% +$242K 2.17% 9
2024
Q1 		$10.8M Buy
25,938
+496
+2% +$210K 2.03% 12
2023
Q4 		$10.4M Buy
25,442
+355
+1% +$131K 2.25% 10
2023
Q3 		$8.72M Buy
25,087
+510
+2% +$178K 2.11% 13
2023
Q2 		$8.65M Buy
24,577
+433
+2% +$146K 2.1% 14
2023
Q1 		$7.61M Sell
24,144
-97
-0.4% -$29.1K 1.89% 16
2022
Q4 		$7M Buy
24,241
+250
+1% +$76.2K 1.87% 15
2022
Q3 		$6.95M Buy
23,991
+270
+1% +$77.7K 1.94% 11
2022
Q2 		$6.68M Sell
23,721
-2,178
-8% -$583K 1.79% 18
2022
Q1 		$6.76M Buy
25,899
+2,480
+11% +$589K 1.39% 23
2021
Q4 		$5.14M Buy
23,419
+3,012
+15% +$586K 0.98% 27
2021
Q3 		$3.7M Sell
20,407
-1,035
-5% -$202K 0.8% 38
2021
Q2 		$4.32M Buy
21,442
+3,157
+17% +$660K 0.92% 33
2021
Q1 		$3.93M Buy
18,285
+14,570
+392% +$3.2M 0.92% 33
2020
Q4 		$878K Buy
+3,715
New +$852K 0.22% 69

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Davenport & Co
Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return
Montrusco Bolton Investments
Montrusco Bolton Investments Montreal, Quebec, Canada $5.77B AUM 24.61% 1-Year Est. Return
Birch Hill Investment Advisors
Birch Hill Investment Advisors Boston, Massachusetts $2.43B AUM 15.45% 1-Year Est. Return
Fjarde Ap-fonden
Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return
MN Services Vermogensbeheer
MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return
Czech National Bank
Czech National Bank Prague, Czech Republic $18.9B AUM 36.24% 1-Year Est. Return
Gateway Investment Advisers
Gateway Investment Advisers Cincinnati, Ohio $11B AUM 34.31% 1-Year Est. Return
IFM Investors
IFM Investors Melbourne, Australia $16B AUM 33.69% 1-Year Est. Return

Fagan Associates's VRTX Position: Q3 2026 in Review

Fagan Associates increased its Vertex Pharmaceuticals (VRTX) stake by 4% in Q3 2026, buying an estimated $536K and bringing the position to 27,475 shares worth $14.4M. The position accounts for 1.67% of the portfolio, ranked #14.

Fagan Associates first reported a position in VRTX in Q4 2020 and has held it in 24 quarters since. 277 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Fagan Associates held 27,475 shares of Vertex Pharmaceuticals worth $14.4M as of Q3 2026.
  • Fagan Associates bought 1,046 Vertex Pharmaceuticals shares in Q3 2026, an estimated $536K.
  • Vertex Pharmaceuticals made up 1.67% of Fagan Associates's portfolio in Q3 2026, its #14 holding.
  • Fagan Associates first reported a position in Vertex Pharmaceuticals in Q4 2020 and has held it in 24 quarters since.
  • 277 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Fagan Associates's 13F filing for Q3 2026, filed 13 Oct 2026.